Histamine
metaboliteHistamine dampens platelet activation and thromboinflammation, protecting against coronary microthrombosis in acute MI.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleMast-cell/basophil mediator; antiplatelet and endothelial-protective effects post-MI.
Also acts inEndothelial activation/erosion
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresShared / rises in both
R — rupture / Type-I67
C — confounder / Type-II67
A — assay feasibility42
E — evidence strength38
T1DI (composite)8
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressn/a
Coverage: 5/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 9 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Histamine deficiency facilitates coronary microthrombosis after myocardial infarction by increasing neutrophil-platelet interactions.Journal of cellular and molecular medicine · 2020 · PMID 32064748 · doi